Decentralised point-of-care testing for acute, chronic and infectious disease - benefits and challenges
Pathology
; 55(Supplement 1):S7, 2023.
Article
in English
| EMBASE | ID: covidwho-2233099
ABSTRACT
The COVID-19 pandemic has reinforced Australia's need for diagnostic testing frameworks that are well-prepared, well-resourced, responsive, appropriately governed, scalable, interdisciplinary and collaborative.1 Point-of-care (POC) technologies offer diagnostic solutions capable of delivering individual, community and public health benefits in settings where a) laboratory testing is not available, b) rapid turn-around time is needed, c) high loss to follow-up occurs in high-risk populations with standard of care cascades and/or d) disease transmission rates exceed laboratory response capacity. Key translational research derived from collaborative point-of-care testing networks for a) diabetes management (238 remote health services;3,233 operators;172,069 HbA1c and 51,379 urine albumincreatinine ratio tests), b) acute care (106 remote health services;2,279 operators;32,950 blood gas, 32,689 cardiac troponin, 46,418 urea/electrolytes, 48,193 international normalised ratio tests), c) hepatitis C virus (HCV) (41 sites;110 operators;5,733 HCV tests;4,978 RNA, 755 antibody), d) syphilis screening (156 sites;1,412 operators), e) chlamydia, gonorrhea or trichomonas (51 sites;795 operators;>50,000 tests) or f) COVID-19 (101 remote health services, 733 operators, 72,624 tests) will be used to highlight operational, clinical, public health, and economic benefits of POC testing. Challenges associated with scale-up and accreditation pathways for decentralised POC testing will be discussed. Reference 1. Revised Testing Framework for COVID-19 in Australia, March 2022 Version 2.1. Communicable Disease Network Australia and Public Health Laboratory Network. Copyright © 2022
accreditation; acute disease; albumin to creatinine ratio; Australia; blood gas; Chlamydia; chronic disease; chronic infection; conference abstract; controlled study; coronavirus disease 2019; diabetes mellitus; emergency care; follow up; gonorrhea; health care quality; Hepatitis C virus; high risk population; human; international normalized ratio; laboratory test; nonhuman; pandemic; point of care testing; public health; scale up; syphilis; translational research; Trichomonas; electrolyte; endogenous compound; hemoglobin A1c; troponin; urea
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Cohort study
/
Diagnostic study
/
Prognostic study
Language:
English
Journal:
Pathology
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS